electroCore (NASDAQ:ECOR) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of electroCore (NASDAQ:ECOR) in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

electroCore Price Performance

electroCore stock opened at $9.55 on Thursday. The stock’s 50 day moving average price is $16.16 and its 200 day moving average price is $12.26. electroCore has a 1-year low of $5.32 and a 1-year high of $19.49. The company has a market cap of $63.56 million, a PE ratio of -5.22 and a beta of 0.24.

Hedge Funds Weigh In On electroCore

Large investors have recently made changes to their positions in the stock. HighTower Advisors LLC purchased a new stake in electroCore during the third quarter worth about $255,000. Geode Capital Management LLC lifted its position in shares of electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after acquiring an additional 5,951 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of electroCore by 31,250.0% during the 4th quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock worth $61,000 after acquiring an additional 3,750 shares in the last quarter. DnB Asset Management AS acquired a new stake in shares of electroCore in the 4th quarter worth approximately $180,000. Finally, Renaissance Technologies LLC grew its holdings in shares of electroCore by 80.6% in the 4th quarter. Renaissance Technologies LLC now owns 131,786 shares of the company’s stock worth $2,136,000 after acquiring an additional 58,800 shares during the period. Hedge funds and other institutional investors own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.